MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Abroad (travel likely)RecruitingPHASE3

Conditions

Polycythemia Vera

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • Royal United Hospital, Bath, United Kingdom

  • Belfast City Hospital, Belfast, United Kingdom

  • Birmingham Heartlands Hospital, Birmingham, United Kingdom

  • Blackpool Victoria Hospital, Blackpool, United Kingdom

  • Royal Bournemouth Hospital, Bournemouth, United Kingdom

  • Southmead Hospital, Bristol, United Kingdom

  • Addenbrooke's Hospital, Cambridge, United Kingdom

  • Kent and Canterbury Hospital, Canterbury, United Kingdom

  • University Hospital of Wales, Cardiff, United Kingdom

  • St Richard's Hospital, Chichester, United Kingdom

  • Colchester Hospital, Colchester, United Kingdom

  • Castle Hill Hospital, Cottingham, United Kingdom

  • Russells Hall Hospital, Dudley, United Kingdom

  • Western General Hospital, Edinburgh, United Kingdom

  • Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Gloucestershire Royal Hospital, Gloucester, United Kingdom

  • Calderdale Royal Hospital, Halifax, United Kingdom

  • Huddersfield Royal Infirmary, Huddersfield, United Kingdom

  • Raigmore Hospital, Inverness, United Kingdom

  • Kettering General Hospital, Kettering, United Kingdom

  • Leicester Royal Infirmary, Leicester, United Kingdom

  • St John's Hospital, Livingston, United Kingdom

  • University College Hospital, London, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • St George's Hospital, London, United Kingdom

  • Wythenshawe Hospital, Manchester, United Kingdom

  • Arrowe Park Hospital, Metropolitan Borough of Wirral, United Kingdom

  • The James Cook University Hospital, Middlesbrough, United Kingdom

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Royal Gwent Hospital, Newport, United Kingdom

  • North Tyneside General Hospital, North Shields, United Kingdom

  • Northampton General Hospital, Northampton, United Kingdom

  • Norfolk and Norwich University Hospital, Norwich, United Kingdom

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Churchill Hospital, Oxford, United Kingdom

  • Royal Berkshire Hospital, Reading, United Kingdom

  • Halton Hospital, Runcorn, United Kingdom

  • Wexham Park Hospital, Slough, United Kingdom

  • Southampton General Hospital, Southampton, United Kingdom

  • Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom

  • Sunderland Royal Hospital, Sunderland, United Kingdom

  • Good Hope Hospital, Sutton Coldfield, United Kingdom

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Warwick Hospital, Warwick, United Kingdom

  • New Cross Hospital, Wolverhampton, United Kingdom

  • Worthing Hospital, Worthing, United Kingdom

Study leads
  • Claire Harrison

    Principal Investigator

    Acting on behalf of the Sponsor (UK), Guy's Hospital, London, UK, SE1 9RT

  • Jean-Jacques Kiladjian

    Principal Investigator

    (France) Clinical Investigations Center, Saint-Louis Hospital, Paris, France